Cue Biopharma is trading at $26.10, down 5.64%, with no clear catalyst identified for the October 12 decline. - No company-specific announcement or clear catalyst was identified; company news centers on earlier CUE-221 trial results, not a new event. - Broader market indices were nearly flat and XBI was down 0.4%; the available evidence does not establish a market or sector explanation. - The October 9 rally preceded the decline but does not confirm today's cause; intraday volume information was unavailable.